Candel Therapeutics Prostate Cancer Therapy Shows Promise

Exec Edge

2024-12-12

By Karen Roman

Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.

“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.

Contact:

Exec Edge

Editor@Executives-edge.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2490894217"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490894217\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2490894217?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DbMe6Vs5edsmnzU5zbvvwQ--~B/aD03NDI7dz03MDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/exec_edge_220/b02f07337ac03aed6bcfa81a1da6b331","is_english":true,"pubTime":"2024-12-12 02:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490894217","market":"us","top_or_hot":-1,"title":"Candel Therapeutics Prostate Cancer Therapy Shows Promise","media":"Exec Edge","content":"<html><body><p><img height=\"742\" src=\"https://s1.yimg.com/uu/api/res/1.2/W7pHYKtw3DABcJ544ir_rg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/b02f07337ac03aed6bcfa81a1da6b331\" width=\"709\"/></p>\n<p>By Karen Roman</p>\n<p><a href=\"https://laohu8.com/S/CADL\">Candel Therapeutics, Inc.</a> (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.</p>\n<p>“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.</p>\n<div>\n<div>\n  Contact:\n </div>\n</div>\n<p>Exec Edge</p>\n<p>Editor@Executives-edge.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Prostate Cancer Therapy Shows Promise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Prostate Cancer Therapy Shows Promise\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Exec Edge</strong><span class=\"h-time small\">2024-12-12 02:07</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><img height=\"742\" src=\"https://s1.yimg.com/uu/api/res/1.2/W7pHYKtw3DABcJ544ir_rg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/b02f07337ac03aed6bcfa81a1da6b331\" width=\"709\"/></p>\n<p>By Karen Roman</p>\n<p><a href=\"https://laohu8.com/S/CADL\">Candel Therapeutics, Inc.</a> (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.</p>\n<p>“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.</p>\n<div>\n<div>\n  Contact:\n </div>\n</div>\n<p>Exec Edge</p>\n<p>Editor@Executives-edge.com</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/candel-therapeutics-prostate-cancer-therapy-180716886.html\">Exec Edge</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-prostate-cancer-therapy-180716886.html","article_id":"2490894217","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DbMe6Vs5edsmnzU5zbvvwQ--~B/aD03NDI7dz03MDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/exec_edge_220/b02f07337ac03aed6bcfa81a1da6b331"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490894217","pubTimestamp":1733940436,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Candel Therapeutics, Inc.  said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4539":"次新股","CADL":"Candel Therapeutics, Inc."},"translate_title":"Candel Therapeutics前列腺癌疗法显示出希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":1,"LENZ":1},"content_text":"By Karen Roman\nCandel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients.\n“We look forward to working with the FDA, as a next step, to seek approval to bring CAN-2409 to patients in the U.S., and advance our broad viral immunotherapy pipeline across other large oncology indications of high unmet need,” said Paul Peter Tak, Candel’s President and CEO.\n\n\n  Contact:\n \n\nExec Edge\nEditor@Executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}